P10636 |
TAU_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 |
TAU_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P10636 |
TAU_HUMAN |
Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 |
TAU_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P10636 |
TAU_HUMAN |
Parkinsonism [ICD-11: 8A00] |
P10636 |
TAU_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 |
TAU_HUMAN |
Neurodegenerative disorder [ICD-11: 8A20-8A23] |
O75874 |
IDHC_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 |
IDHC_HUMAN |
Liver cancer [ICD-11: 2C12] |
O75874 |
IDHC_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
O75874 |
IDHC_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
O75874 |
IDHC_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 |
IDHC_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P43220 |
GLP1R_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
P43220 |
GLP1R_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P43220 |
GLP1R_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P43220 |
GLP1R_HUMAN |
Type-1/2 diabete [ICD-11: 5A10-5A11] |
P43220 |
GLP1R_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P43220 |
GLP1R_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P43220 |
GLP1R_HUMAN |
Dyspepsia [ICD-11: MD92] |
P43220 |
GLP1R_HUMAN |
Irritable bowel syndrome [ICD-11: DD91] |
P43220 |
GLP1R_HUMAN |
Intracranial injury [ICD-11: NA07] |
P43220 |
GLP1R_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
P84022 |
SMAD3_HUMAN |
Herpes simplex infection [ICD-11: 1F00] |
P84022 |
SMAD3_HUMAN |
Kidney fibrosis [ICD-11: GC01] |
Q03431 |
PTH1R_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
Q03431 |
PTH1R_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
O94782 |
UBP1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P42858 |
HD_HUMAN |
Choreiform disorder [ICD-11: 8A01] |
P51151 |
RAB9A_HUMAN |
Fungal infection [ICD-11: 1F29-1F2F] |
Q00987 |
MDM2_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q00987 |
MDM2_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
Q00987 |
MDM2_HUMAN |
Myeloproliferative neoplasm [ICD-11: 2A20] |
Q00987 |
MDM2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q00987 |
MDM2_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
Q00987 |
MDM2_HUMAN |
Myelodysplastic syndrome [ICD-11: 2A37] |
Q00987 |
MDM2_HUMAN |
Neuroendocrine carcinoma [ICD-11: 2C34] |
Q00987 |
MDM2_HUMAN |
Liposarcoma [ICD-11: 2B59] |
Q00987 |
MDM2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q00987 |
MDM2_HUMAN |
Prostate cancer [ICD-11: 2C82] |
Q00987 |
MDM2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q00987 |
MDM2_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |